Latest: FDA Approves New Biosimilar for Oncology Treatment

HistoSonics Valued at $2.25B After Major Acquisition to Accelerate Histotripsy Growth

0 Mins
What You Should Know: – HistoSonics, the company behind the non-invasive Edison® Histotripsy System, has announced a management-led majority stake acquisition by a syndicate of private and public investors, including K5 Global, Bezos Expeditions, and Wellington Management. – The transaction values the company at approximately $2.25 billion and is expected to accelerate the growth of ... Read More
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago